Main
esophageal cancer, death, ESCC
OESOPHAGEAL CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer and accounts for approximately 84% of all esophageal cancer casesSystemic chemotherapy remains the backbone of treatment of unresectable or metastatic ESCC. Although 5-fluorouracil (5-FU) or paclitaxel plus cisplatin has been widely used in the first-line setting, programmed cell death protein 1 (PD-1) inhibitors in combination with chemotherapy showed improved efficacy compared with chemotherapy alone in phase 3 trialsAdvances in immunotherapy have uncovered programmed cell death protein ligand 1 (PD-L1) as a potential therapeutic target and biomarker for patients with ESCC. PD-L1 overexpression was observed in up to 40% of ESCCSerplulimab (HLX10) is a fully humanized, selective immunoglobulin G4 monoclonal antibody against PD-1 receptor